A synthetic E7 gene of human papillomavirus type 16 that yields enhanced expression of the protein in mammalian cells and is useful for DNA immunization studies.
about
Papillomavirus genome structure, expression, and post-transcriptional regulationGeneralized substitution of isoencoding codons shortens the duration of papillomavirus L1 protein expression in transiently gene-transfected keratinocytes due to cell differentiationCRPV genomes with synonymous codon optimizations in the CRPV E7 gene show phenotypic differences in growth and altered immunity upon E7 vaccinationCharacterization and whole genome analysis of human papillomavirus type 16 e1-1374^63nt variantsA downstream polyadenylation element in human papillomavirus type 16 L2 encodes multiple GGG motifs and interacts with hnRNP H.Therapeutic HPV DNA vaccines.Human papillomavirus E7 requires the protease calpain to degrade the retinoblastoma protein.A multiagent filovirus DNA vaccine delivered by intramuscular electroporation completely protects mice from ebola and Marburg virus challenge.Optimization of codon usage enhances the immunogenicity of a DNA vaccine encoding mycobacterial antigen Ag85BLow-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responsesGene codon composition determines differentiation-dependent expression of a viral capsid gene in keratinocytes in vitro and in vivo.Determinants of baseline seroreactivity to human papillomavirus type 16 in the Ludwig-McGill cohort study.Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine.A DNA vaccine for venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates.Papillomaviruses: Viral evolution, cancer and evolutionary medicineCodon optimization of the human papillomavirus E7 oncogene induces a CD8+ T cell response to a cryptic epitope not harbored by wild-type E7The efficacy of a DNA vaccine containing inserted and replicated regions of the E7 gene for treatment of HPV-16 induced tumors.Effects of the fusion design and immunization route on the immunogenicity of Ag85A-Mtb32 in adenoviral vectored tuberculosis vaccine.Cancer, Warts, or Asymptomatic Infections: Clinical Presentation Matches Codon Usage Preferences in Human PapillomavirusesVirus-Like Particles Harboring CCL19, IL-2 and HPV16 E7 Elicit Protective T Cell Responses in HLA-A2 Transgenic MicePreventive and Therapeutic Vaccines against Human Papillomaviruses Associated Cervical CancersRedirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system.Vaccines against human papillomavirus: perspectives for controlling cervical cancer.Imaging of genetically engineered T cells by PET using gold nanoparticles complexed to Copper-64DNA vaccination and gene therapy: optimization and delivery for cancer therapy.Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.Therapeutic vaccines against human papillomavirus and cervical cancer.tRNASer(CGA) differentially regulates expression of wild-type and codon-modified papillomavirus L1 genes.Codon usage bias in Chlamydia trachomatis and the effect of codon modification in the MOMP gene on immune responses to vaccination.Codon usage roles in human papillomavirus.Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines.Interkeratin peptide-protein interactions that promote HPV16 E7 gene expression.The first hydrophobic region of the HPV16 E5 protein determines protein cellular location and facilitates anchorage-independent growth.The E5 protein of the human papillomavirus type 16 down-regulates HLA-I surface expression in calnexin-expressing but not in calnexin-deficient cells.Telomere Dynamics in Immune Senescence and Exhaustion Triggered by Chronic Viral Infection.Effects of hemagglutinin-neuraminidase protein mutations on cell-cell fusion mediated by human parainfluenza type 2 virusCodon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene.High-level expression and immunogenicity of a porcine circovirus type 2 capsid protein through codon optimization in Pichia pastoris.Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model.Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.
P2860
Q22255483-3B911AE8-2021-4AAD-BA7A-FCC46CA5BD3DQ27480991-331C6BED-C6EA-4073-BE34-87B457F2646CQ28473368-07198A63-B390-47A2-A193-99DE70945CC0Q28481495-5970FE8C-778D-415B-B5DA-5D698FA8D275Q30789709-048E52F4-E8BC-4994-959C-19E513CCA691Q33936427-4611022D-C4D4-47F4-9882-13D73C422D37Q34007987-6C5BA877-6751-48EF-B370-471B1383B03CQ34033322-4EEEE68D-7095-47E9-8915-FD237E924981Q34033825-EE4197CF-6DA2-46BB-9C79-7157789A5922Q34045548-345B2407-7A04-4542-81F3-B2E932C80253Q34097123-25322F72-B994-4FF4-ACA3-F759903FC9B7Q34587057-44FC204E-6C43-487A-A393-140F52F255C1Q34657676-1BB9A107-62CB-459E-901C-9F694813EE07Q35066196-1C707094-E346-40F2-B466-29173C70196CQ35166924-B3613818-4549-498E-A772-A44A1791A36AQ35208290-8B90E9E2-59A9-47A3-8943-78F554A7A458Q35828417-B498C70F-DF60-4CBB-9FD9-B8941DFF0946Q35887146-53AB7356-7B69-4BFE-A52E-0280FA8D238AQ36023244-C2200374-105E-4EE0-9CD2-3FB25BF16116Q36540598-1491E2B4-4313-487F-89B4-C746357B44F0Q36652548-597477F7-6A0E-45C2-98C4-A3A543D32234Q36713904-5758F4E5-6B42-4E5D-A67D-771A6F024A1CQ36899058-59DF50C3-7F44-4CF1-A09E-14625CB5C4E6Q37019430-E7A9E6F4-93E7-438D-BD6F-00AFCB8CBAD4Q37259636-396434D3-5ECB-436F-B65F-06DB55D2FD99Q37348901-19EEFD32-DFDB-4F65-83F9-F79B5AA1A764Q37418916-945916FC-85FB-4A50-9DEB-D76A753DDF65Q37509240-048BC2FD-49B8-42F4-976B-4C7A664D3FC1Q37859692-7D8DEB42-B9DF-427E-B87E-B0CD8373C3E7Q37949297-3F9277CC-6322-4967-9DBC-1183EE3ABC93Q39320921-3F0398FC-3898-45C2-951D-3044856B3E82Q39644878-090A9EA2-3511-4552-9400-DB26E5BC8842Q40008672-CFFAFA3F-C3D1-4EB0-B4F3-4978F2077FAEQ40059928-D7E4728A-B461-4666-8C6D-6551F4941A8CQ41923721-0BA06540-1175-4878-AC36-5BE05134C822Q42081316-BF36602E-ED25-4FC7-9442-0CBE79E488BEQ42983652-9A4450F6-4CE8-4845-AC94-F7325F953944Q43741583-D778863D-A999-42E0-8060-6AC00216BD76Q43854654-694156A1-2431-4E53-9C40-F4D609E71A9BQ50115667-83FDCC0F-303F-4D9D-AB0A-8C6BA3A1F36C
P2860
A synthetic E7 gene of human papillomavirus type 16 that yields enhanced expression of the protein in mammalian cells and is useful for DNA immunization studies.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
A synthetic E7 gene of human p ...... for DNA immunization studies.
@ast
A synthetic E7 gene of human p ...... for DNA immunization studies.
@en
A synthetic E7 gene of human p ...... for DNA immunization studies.
@nl
type
label
A synthetic E7 gene of human p ...... for DNA immunization studies.
@ast
A synthetic E7 gene of human p ...... for DNA immunization studies.
@en
A synthetic E7 gene of human p ...... for DNA immunization studies.
@nl
prefLabel
A synthetic E7 gene of human p ...... for DNA immunization studies.
@ast
A synthetic E7 gene of human p ...... for DNA immunization studies.
@en
A synthetic E7 gene of human p ...... for DNA immunization studies.
@nl
P2860
P1433
P1476
A synthetic E7 gene of human p ...... for DNA immunization studies.
@en
P2093
Victoria Juárez
P2860
P304
P356
10.1128/JVI.77.8.4928-4937.2003
P407
P577
2003-04-01T00:00:00Z